Literature DB >> 18550873

Vaccine preparedness--are we ready for the next influenza pandemic?

Peter F Wright1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18550873     DOI： 10.1056/NEJMp0803650

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

1.  Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations.

Authors:  Bryan B Hsu; Sze Yinn Wong; Paula T Hammond; Jianzhu Chen; Alexander M Klibanov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

2.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Authors:  Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham
Journal:  Contemp Clin Trials       Date:  2015-08-12       Impact factor: 2.226

4.  Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.

Authors:  Nayer Khazeni; David W Hutton; Alan M Garber; Douglas K Owens
Journal:  Ann Intern Med       Date:  2009-12-15       Impact factor: 25.391

5.  Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies.

Authors:  Alida Ault; Alyse M Zajac; Wing-Pui Kong; J Patrick Gorres; Michael Royals; Chih-Jen Wei; Saran Bao; Zhi-yong Yang; Stephanie E Reedy; Tracy L Sturgill; Allen E Page; Jennifer Donofrio-Newman; Amanda A Adams; Udeni B R Balasuriya; David W Horohov; Thomas M Chambers; Gary J Nabel; Srinivas S Rao
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

6.  Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains.

Authors:  Jian Zhou; Fan Yang; Jinghui Yang; Lei Ma; Yina Cun; Shaohui Song; Guoyang Liao
Journal:  Hum Vaccin Immunother       Date:  2016-09-20       Impact factor: 3.452

7.  Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Authors:  Larry R Smith; Walter Wodal; Brian A Crowe; Astrid Kerschbaum; Peter Bruehl; Michael G Schwendinger; Helga Savidis-Dacho; Sean M Sullivan; Mark Shlapobersky; Jukka Hartikka; Alain Rolland; P Noel Barrett; Otfried Kistner
Journal:  Hum Vaccin Immunother       Date:  2013-03-06       Impact factor: 3.452

8.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Authors:  David L Gordon; Dimitar Sajkov; Richard J Woodman; Yoshikazu Honda-Okubo; Manon M J Cox; Susanne Heinzel; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-17       Impact factor: 3.641

9.  Mitigation approaches to combat the flu pandemic.

Authors:  Raman Chawla; Rakesh Kumar Sharma; Deepali Madaan; Neha Dubey; Rajesh Arora; Rajeev Goel; Shefali Singh; Vinod Kaushik; Pankaj Kumar Singh; Vivek Chabbra; Janak Raj Bhardwaj
Journal:  J Glob Infect Dis       Date:  2009-07

10.  Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene.

Authors:  Attapon Kamlangdee; Brock Kingstad-Bakke; Tavis K Anderson; Tony L Goldberg; Jorge E Osorio
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.